Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 8/20 | 0.51 |
| ▸ | ATF4 | P18848 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CXCR6 | O00574 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3869029 | 1.00 | MCHR1 (0.51) | MCHR1ATF4POLBSMN1; SMN2CXCR6 | |
| SCHEMBL4668786 | 0.97 | MCHR1 (0.55) | MCHR1ATF4POLB | |
| SCHEMBL4668785 | 0.97 | MCHR1 (0.55) | MCHR1ATF4POLB | |
| SCHEMBL3872107 | 0.88 | MCHR1 (0.61) | MCHR1ATF4POLB | |
| SCHEMBL3872106 | 0.88 | MCHR1 (0.61) | MCHR1ATF4POLB | |
| SCHEMBL3869586 | 0.86 | ATF4 (0.66) | ATF4POLBCXCR6LTA4HMAPT | |
| SCHEMBL3869587 | 0.86 | ATF4 (0.66) | ATF4POLBCXCR6LTA4HMAPT | |
| SCHEMBL3870007 | 0.81 | L3MBTL1 (0.48) | MCHR1ATF4SMN1; SMN2CXCR6LTA4H | |
| SCHEMBL3870004 | 0.81 | L3MBTL1 (0.48) | MCHR1ATF4SMN1; SMN2CXCR6LTA4H | |
| SCHEMBL3871401 | 0.79 | MCHR1 (0.53) | MCHR1ATF4SMN1; SMN2CXCR6LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1891064-B1 | N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS | ALMIRALL SA (ES) | 2009-09-02 | — | — | EP | claimed |
| US-20090130090-A1 | N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-05-21 | — | — | US | claimed |
| EP-1891064-B1 | N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS | ALMIRALL SA (ES) | 2009-09-02 | — | — | EP | disclosed |
| US-20090130090-A1 | N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090130090-A1 | N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists | CCR1, CCR3, CCR8 | MCHR1 414/4885ATF4 577/4885POLB 1794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.